Powered by lexis nexis

ExoDx® Prostate(IntelliScore) (EPI) Recommended in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection

Jan 31, 2019 - PR Newswire

PR Newswire

 Bio-Techne Corporation (NASDAQ:TECH) today announced the National Comprehensive Cancer Network (NCCN) decision to include EPI as a recommended test in their Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection (Version 1.2019).

The updated treatment algorithm includes EPI testing prior to a first prostate biopsy or after a negative biopsy to assist patients and urologists in further defining the probability of high-grade cancer ...